CIK 0001822462 · Non-accelerated filer<br>Smaller reporting company
Foghorn Therapeutics Inc.
Sign in to watch- Ticker
- FHTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-586-3100
- Business address
- 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-26 | Cavalie Fanny Chief Strategy/Bus Ops Officer | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2023-01-26 | Bellon Steven F. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2023-01-26 | Costa Carlos Chief People Officer | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2023-01-26 | LaCascia Michael Chief Legal Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2023-01-26 | GOTTSCHALK ADRIAN Chief Executive Officer | Grant or award · Stock Option (right to buy) | +280,000 | 280,000 | ||
| 2023-01-26 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2022-10-27 | Lynch Thomas J. Jr. Director | Grant or award · Stock Options (Right to buy) | +32,000 | $8.23 | $263K | 32,000 |
| 2022-10-25 | GOTTSCHALK ADRIAN Chief Executive Officer | Other acquisition | +4,371 | 67,371 | ||
| 2022-10-25 | GOTTSCHALK ADRIAN Chief Executive Officer | Other disposition | −4,371 | 444,333 | ||
| 2022-09-16 | GOTTSCHALK ADRIAN Chief Executive Officer | Option exercise | +40,000 | $0.54 | $22K | 186,479 |
| 2022-09-16 | GOTTSCHALK ADRIAN Chief Executive Officer | Option exercise · Stock Option (right to buy) | −40,000 | 418,925 | ||
| 2022-09-13 | GILL SIMBA Director | Gift | −47,939 | 34,061 | ||
| 2022-09-12 | GILL SIMBA Director | Option exercise | +82,000 | $0.73 | $60K | 82,000 |
| 2022-09-12 | GILL SIMBA Director | Option exercise · Stock Options (Right to buy) | −82,000 | 107,188 | ||
| 2022-08-16 | PARSHALL B LYNNE Director | Grant or award · Stock Options (Right to buy) | +32,000 | $16.34 | $523K | 32,000 |
| 2022-08-11 | Bellon Steven F. Chief Scientific Officer | Option exercise | +1,858 | $3.72 | $7K | 121,957 |
| 2022-08-11 | Bellon Steven F. Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −1,858 | 3,716 | ||
| 2022-08-01 | Costa Carlos Chief People Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-06-21 | Biller Scott Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 | ||
| 2022-06-21 | Mendelsohn Michael Director | Grant or award · Stock Options (Right to buy) | +16,000 | 16,000 |
Page 6 of 9 · 177 trades